Q2 EPS Forecast for Nurix Therapeutics Raised by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Research analysts at HC Wainwright lifted their Q2 2026 earnings estimates for Nurix Therapeutics in a note issued to investors on Friday, April 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.73) for the quarter, up from their previous estimate of ($0.74). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.79) EPS and FY2026 earnings at ($3.08) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. The business had revenue of $6.25 million for the quarter, compared to the consensus estimate of $14.25 million.

NRIX has been the subject of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Thursday, January 22nd. Morgan Stanley set a $36.00 price objective on shares of Nurix Therapeutics and gave the company an “overweight” rating in a research report on Thursday, January 8th. Stifel Nicolaus increased their price objective on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Wells Fargo & Company lowered their price objective on shares of Nurix Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Thursday, April 9th. Finally, Piper Sandler increased their price objective on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.46.

Nurix Therapeutics Stock Up 2.5%

NRIX stock opened at $16.30 on Tuesday. Nurix Therapeutics has a 52 week low of $8.19 and a 52 week high of $22.50. The company has a fifty day simple moving average of $15.65 and a two-hundred day simple moving average of $15.48. The firm has a market capitalization of $1.69 billion, a P/E ratio of -5.16 and a beta of 1.97.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Flax Pond Capital LLC purchased a new position in Nurix Therapeutics in the 4th quarter worth about $1,521,000. Caitong International Asset Management Co. Ltd purchased a new position in Nurix Therapeutics in the 4th quarter worth about $53,000. Seven Fleet Capital Management LP purchased a new position in Nurix Therapeutics in the 4th quarter worth about $379,000. Invesco Ltd. increased its stake in Nurix Therapeutics by 115.0% in the 4th quarter. Invesco Ltd. now owns 343,830 shares of the company’s stock worth $6,522,000 after buying an additional 183,909 shares during the period. Finally, Voloridge Investment Management LLC increased its stake in Nurix Therapeutics by 3.6% in the 4th quarter. Voloridge Investment Management LLC now owns 154,459 shares of the company’s stock worth $2,930,000 after buying an additional 5,318 shares during the period.

Insider Activity

In other news, insider Gwenn Hansen sold 4,895 shares of the firm’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $81,257.00. Following the completion of the sale, the insider owned 83,672 shares in the company, valued at approximately $1,388,955.20. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 3,661 shares of the firm’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares of the company’s stock, valued at $754,088.20. This trade represents a 7.46% decrease in their position. The SEC filing for this sale provides additional information. 6.70% of the stock is currently owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.